The Quantellect read.As of Nov 19, 2026, 13 active firms cover Procept Biorobotics Corp: 6 rate it Buy or better, 6 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. Targets range widely, $20.00 to $51.00 (about 2.5x), a sign of real disagreement on valuation. The average target of $28.64 sits 14% above the current $25.19. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.43 next quarter toward $-1.24 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 active firms
Neutral
Strong Buy00%
Buy646%
Neutral646%
Sell18%
Strong Sell00%
Based on 13 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$28.64
+13.7% upside
Average target across 11 active firms as of Nov 19, 2026 vs $25.19 current
Highest Target$51.00
Average Target$28.64
Lowest Target$20.00
Detailed analyst forecasts for PRCT
Showing 1–13 of 13 named analysts shown · 13 active firms in the rating projection
As of Nov 19, 2026, 6 of 13 active firms rate PRCT a Buy (6 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PRCT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.43
Range $-0.52 – $-0.34 · 10 analysts · -22% YoY
Next period, 10 analysts expect Procept Biorobotics Corp to earn $-0.43 a share (range $-0.52 – $-0.34), versus $-0.56 a year earlier. Full-year consensus is $-1.72, growing to $-1.24 the year after.
REVENUE · NEXT QUARTER
$104.6M
Range $101.4M – $108.2M · 10 analysts · +26% YoY
Revenue is expected to reach $104.6M (range $101.4M – $108.2M), +25.8% year-over-year. Full-year consensus is $395.3M, rising to $473.7M next year.
Top analysts covering Procept Biorobotics Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PRCT.
#1
MC
Mason Carrico
Stephens & Co. · Rank #178
Buy
$70.00+177.9% to target
Overall win rate
40%
+ Follow
#2
Ryan Zimmerman
BTIG · Rank #212
Neutral
No targeton PRCT
Overall win rate
37%
+ Follow
#3
Vijay Kumar
Evercore ISI Group · Rank #331
Buy
$23.00-8.7% to target
Overall win rate
36%
+ Follow
#4
Richard Newitter
Truist Securities · Rank #532
Neutral
$21.00-16.6% to target
Overall win rate
30%
+ Follow
#5
Matt O'Brien
Piper Sandler · Rank #561
Buy
$25.00-0.8% to target
Overall win rate
25%
+ Follow
PRCT stock forecast FAQ
What is PRCT's average 12-month price target?+
The 11 active firms with a live target average $28.64 for Procept Biorobotics Corp over the next 12 months, ranging from a $51.00 high to a $20.00 low, as of Nov 19, 2026.
Is PRCT stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 13 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 6 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PRCT?+
The Street-high target is $51.00 (Morgan Stanley), and the Street-low is $20.00 (UBS). The average of all 11 active-firm targets is $28.64.
How many active Wall Street firms cover PRCT?+
13 active firms have a recognized rating on Procept Biorobotics Corp as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PRCT?+
Among analysts who currently cover PRCT, Mason Carrico of Stephens & Co. has the strongest overall Quantellect track record (Rank #178). Their current call is Buy with a $70.00 target.
What is Procept Biorobotics Corp's projected EPS for next quarter?+
The consensus estimate is $-0.43 per share (range $-0.52 – $-0.34) across 10 analysts. Full-year EPS is projected at $-1.72, rising to $-1.24 the following year.
How much revenue is Procept Biorobotics Corp expected to report next quarter?+
Consensus revenue is $104.6M (range $101.4M – $108.2M). Full-year revenue is projected at $395.3M, growing to $473.7M next year.
Have analysts been upgrading or downgrading PRCT lately?+
As of Nov 19, 2026, 6 of 13 active firms rate PRCT a Buy (6 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PRCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.